Commonly used targeted therapies used in melanoma are BRAF inhibitors like vemurafenib and dabrafenib; MEK inhibitors like trametinib and cobimetinib or C-KIT inhibitors like imatinib and nilotinib [18]. Here, MAP2K7 is linked to melanoma.